Regen BioPharma Inc (OTCMKTS: RGBP) (RGBPD) is a biotech sleeper on the bulletin boards that saw its stock jump off $1.25 lows to highs of $2.50 per share on Friday and investors are starting to pay attention. The Company is focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers and currently has 1 IND cleared and 2 INDs submitted with the FDA. Regen offers a diverse pre-clinical pipeline including platform technologies and strong intellectual property protected by multiple patents targeting multiple indications including Solid Tumors, Breast Cancer, Liver Cancer, Myelodysplastic Syndrome, Leukemia, and Bone Marrow Disorders.  

There is a strong core group of investors in the stock who have continued to provide strong support for the company with their continuing accumulation, even throughout the company’s recent 1 for 1,500 reverse split. So, with an OS now of only 3,365,620 in the common stock, the float must be getting very small now. The Company also said it plans to get the rest of the convertible debt off its books and has big plans for 2023. According to CEO David Koos: “The field of immunotherapy is expanding at an unprecedented rate, and this is exemplified by the astronomical rise in the use of immunotherapeutic drugs, which now are believed to possess a 100 billion global annual market. Through positioning ourselves to control multiple means of inducing immunity to survivin, we are seeking to concurrently advance our science, diversify our portfolio and provide possible new revenue streams to shareholders.” We will be updating on Regen BioPharma when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below. 

Regen BioPharma Inc (OTCMKTS: RGBPD) is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, Regen is advancing therapies for treating cancer and autoimmune disorders by modulating the immune checkpoint NR2F6. The company is also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax, tCellVax, Dura-CAR, KimerApt), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). Regen Bio Pharma has been building up a valuable intellectual property portfolio with a growing number of issued patents and over 20 patents pending. 

Regen BioPharma is led by CEO David R. Koos, PhD, DBA who has over 30 years of investment banking and venture capital experience. He has a deep knowledge of start up businesses, public markets and SEC reporting companies. Dr. Koos has extensive relationships with large and small financial institutions, hedge funds and entities that Regen BioPharma expects to leverage for company growth. The Company’s Scientific Advisory Board is extensive and includes Ravinder Reddy, Ph.D. Mohammad Haris, Ph.D. Stefano Bertuzzi, PhD, MPH, David A. Suhy, PhD, Weiping Min, MD, PhD, Amit Patel, MD, MSc, Santosh Kesari, MD, PhD, Rohit Duggal, PhD, William S. Blaner, PhD, Jonathan Baell, PhD, Hinrich Gronemeyer, PhD,  

Regen BioPharma focuses on creating immune checkpoint medicines.  An immune checkpoint is a mechanism by which certain cells of the immune system, typically T cells, are kept from being fully activated. This type of restraint on the immune system is important in the normal functioning of the immune system. However, it is now well-established that many cancers have an ability to trick immune cells into up-regulating their checkpoints and thus shut down the ability of these immune cells to kill the tumor. Several drugs which target checkpoints, termed checkpoint inhibitors, are currently used as standard of care in certain cancers. Regen has been focusing its research on a novel immune checkpoint called NR2F6. 

Regen has a diverse pre-clinical pipeline spanning cell therapies, RNA Vaccines, RNA And DNA therapeutics and small molecule drugs. See list of products currently under development here: 

DuraCAR – Regen has filed patents on shRNA that is designed to inhibit NR2F6 expression in CAR-T Cells and make these CAR-T cells have long-term, durable effectiveness. 

• Currently in pre-clinical development 
• We expect that inhibition of this checkpoint protects CAR-T cells from exhaustion, a common problem of existing CAR-T cell therapies 
• Blocking NR2F6 in CAR-T cells should also make these cells more effective at killing solid tumors. 

KimerApt – Regen has designed a platform technology that uses aptamers that have dual functionality. Aptamers are DNA or RNA sequences that can bind to and inhibit receptors just like antibodies. 

• Regen’s aptamer design has two functions – receptor inhibition and targeted gene inhibition via siRNA delivery 
• This platform technology can be used for a wide variety of immune cell and cancer cell targets 
• Currently being developed as a T cell enhancer and cancer stem cell inhibitor 

Small Molecules Targeting Cancer and Autoimmunity – Regen has identified and filed patents on small molecules that activate and inhibit a novel gene (NR2F6) which controls how the immune system reacts to cancer cells and to inflammatory responses. 

• Objective is to identify small molecules that can activate and inhibit NR2F6 
• Currently in pre-clinical development 

Just a matter of time for $RGBPD. This company holds over 17 patents for cancer treatments & cures including mRNA. Waiting on preclinical results any day. Trading under a 10 million dollar market cap. Upside could be parabolic. https://t.co/TjGDjIWApW

— Gemfinder08 (@clearthinking08) March 14, 2023

 To Find out the inside Scoop on Regen BioPharma Subscribe to newsytrends.com Right Now by entering your Email in the box below

HemaXellerate – Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS 

• HemaXellerate is a personalized cellular therapeutic product designed to stimulate blood production in patients whose bone marrow is not properly functioning. 
• Fat stem cell based product to treat bone marrow that has been damaged 
• Bone marrow damage occurs from radiation, chemo, or chronic conditions 
• HemaXellerate uses patient’s own fat as source of endothelial cells to heal damaged bone marrow 
• United States Food and Drug Administration Investigational New Drug Application cleared (IND #15376) 

dCellVax – Breast Cancer – dCellVax – IND #16200 

• CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.” 
• 10 advanced breast cancer patients 
• Efficacy endpoints at 6 and 12 months 
• Establishment of safety will allow for rapid expansion of patient numbers 
• Currently addressing FDA questions with Dr. Santosh Kesari, head of UCSD Neuro-Oncology program 

tCellVax – Solid tumors – tCellVax – IND #16928 

• tCellVax is a cell-based immunotherapy that stimulates the patient’s immune system through gene silencing of NR2F6 (Solid Tumors). 
• Ex vivo siRNA silencing of NR2F6 in PBMC 
• Silencing using tCellVax induces T cell activation (release of checkpoint inhibition) 
• Initial indications: solid tumors 
• Currently addressing FDA questions with Dr. Santosh Kesari 

DiffronC – Myelodysplastic Syndrome Gene Silencing – DiffronC 

• DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells. 
• siRNA silencing of our newly discovered cancer stem cell target gene 
• Silencing using DiffronC induces differentiation of cancer cells 
• Initial indication is treatment of myelodysplastic syndrome 
• Other indications include solid tumors and acute leukemia 

In Jannuary RGBP announced the filing of a provisional patent application covering the use of survivin-engineered dendritic cells and exosomes for stimulation of anti-cancer immunity. The intellectual property provides additional means of stimulating specific elements of the immune system to selectively seek and destroy cancer cells without harming healthy tissue.  Dendritic cells are the most potent immune cell capable of activating T cells.  T cells are the effectors of the immune system and in the present case are the cells that are involved in killing survivin-expressing tumor cells.  The cancer marker survivin appears to be present on most of the major cancers but not on non-malignant tissues. 

The Company has previously designed dendritic cells for treatment of breast cancer utlizing a process called gene silencing.  The current work capitalized on lessons learned in developing DCellVax[1], as well as novel findings regarding utilizing of exosomes, naturally occurring nanoparticles with ability to modulate the immune system. 

CEO David Koos stated: “The field of immunotherapy is expanding at an unprecedented rate and this is exemplified by the astronomical rise in the use of immunotherapeutic drugs, which now are believed to possess a 100 billion global annual market. Through positioning ourselves to control multiple means of inducing immunity to survivin, we are seeking to concurrently advance our science, diversify our portfolio and provide possible new revenue streams to shareholders.”

$RGBP $RGBPP
Link to Regen presentation at Emerging Growth Conference archivedhttps://t.co/ORUkQjUJD1

— Regen BioPharma Inc. (@TheRegenBio) January 12, 2023

 We have something big coming Subscribe Right Now!

Currently trading at a $11 million market valuation Regen Bio os has dropped to under 5 million shares post the 1 for 1500 reverse stock split earlier this year. Regen Bio is an SEC filer and fully reporting pink current and is eligible to uplist to OTCQB. The Company is pre revenue and has $5 million in liabilities. Regen Bio is focused on developing cellular therapies (including CAR-T cells) as well as RNA and DNA technologies for the treatment of various cancers and currently has 1 IND cleared and 2 INDs submitted with the FDA. Regen offers a diverse pre-clinical pipeline including platform technologies and strong intellectual property protected by multiple patents targeting multiple indications including Solid Tumors, Breast Cancer, Liver Cancer, Myelodysplastic Syndrome, Leukemia, and Bone Marrow Disorders. We will be updating on Regen BioPharma when more details emerge so make sure you are subscribed to newsytrends.com by entering your email below.

Disclosure: we hold no position in Regen BioPharma either long or short and we have not been compensated for this article.